Tomographic myocardial perfusion imaging with technetium-99m-teboroxime at rest and after dipyridamole.
This study was done to determine whether the rapidly clearing myocardial perfusion agent 99mTc-teboroxime (SQ 30217, Cardiotec) could be combined with tomographic imaging to accurately quantify regional myocardial blood flow distribution in anesthetized dogs. Following stenosis of the anterior descending (LAD, n = 10) or circumflex (LCX, n = 5) coronary arteries, teboroxime was administered simultaneously with radioactive microspheres, at rest and following infusion of dipyridamole (0.15 mg/kg/min x 4 min). Tomographic imaging began 1 min after each teboroxime injection and continued for 12 min. For LAD stenosis, when the dipyridamole study was performed first, teboroxime activity in the center of the ischemic region was closely correlated with tissue microsphere content. However, the severity of the dipyridamole-induced flow deficit was underestimated by teboroxime when the rest study was performed first. Our results show that despite rapid myocardial clearance, tomographic imaging of 99mTc-teboroxime provides reasonably accurate quantitation of dipyridamole-induced anterior wall perfusion defects, but that the flow deficit is underestimated when a rest study is performed first or when the defect is located in the inferior wall.
Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Q S
QS
Li
G
G
Solot
T L
TL
Frank
H N
HN
Wagner
L C
LC
Becker
D000818:Animals; D003327:Coronary Disease / Q000000981:diagnostic imaging*; D004176:Dipyridamole; D004285:Dogs; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D007457:Iodine Radioisotopes; D008297:Male; D008863:Microspheres; D008961:Models, Structural; D015609:Organotechnetium Compounds; D010091:Oximes; D014055:Tomography, Emission-Computed
D007457:Iodine Radioisotopes; D015609:Organotechnetium Compounds; D010091:Oximes; D004176:Dipyridamole; C060156:technetium Tc 99m teboroxime